By exploring the relationship between target genes and hub genes in oncogenic signaling pathways that they co-occur with, such as BRAF, PIK3CA, APC, MTOR, etc., that have been proven in targeted therapy, we can choose more suitably potential research mechanisms to improve the prognosis of GC. This evidence concerns the gene BRAF and gastric cancer.